Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe

Thakur, Kunal; Biberger, Anna; Handrich, Alexandra; Rezk, Mourad Farouk

doi:10.1007/s40744-016-0035-1

Cited by 20 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was consistent with the results from the nurse survey, in which these three attributes were also considered by nurses as being the most important attributes when selecting an autoinjector for their patients with RA [17]. In line with the nurse survey, patients rated the attribute of ‘easy to operate the self-injection’ as a strong differentiator for the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector in this survey.…”

Section: Discussionsupporting

confidence: 87%

“…These results were closely aligned with those of the recently reported nurse survey ( n = 149), which was based on the same protocol, and reported that 86% of nurses felt that their patients would prefer the Benepali autoinjector [17]. …”

Section: Discussionsupporting

confidence: 84%

“…Finally, attributes of ‘easy to operate the self-injection’ and ‘button-free autoinjector’ were reported as key drivers impacting patients’ choice of autoinjector. Once again, these results were identical to those reported from the nurse survey, in which these two attributes were also reported as being key drivers impacting nurses’ choice of autoinjector [17]. Altogether, the attributes of the Benepali autoinjector that patients most preferred, which were in alignment with results from the nurse survey [17], can be described as those that make the handling process easier for the patient, suggesting that both patients and nurses in Europe consider the Benepali autoinjector to be easier to handle than the Enbrel MYCLIC autoinjector.…”

Section: Discussionsupporting

confidence: 79%

“…In line with the nurse survey, patients rated the attribute of ‘easy to operate the self-injection’ as a strong differentiator for the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector in this survey. However, the attribute of ‘intuitive/self-explaining usage’, which nurses reported as a strong differentiator for the Benepali autoinjector [17], was considered by patients in this survey as being a moderate differentiator. Finally, attributes of ‘easy to operate the self-injection’ and ‘button-free autoinjector’ were reported as key drivers impacting patients’ choice of autoinjector.…”

Section: Discussionmentioning

confidence: 99%

“…Both Benepali and Enbrel are available as autoinjector devices. In a recent European survey conducted in France, Germany, Italy, Spain, and the United Kingdom (UK), the majority of nurses (86%) reported that their patients would prefer the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector [17]. To determine whether patients were in agreement with nurses, this survey evaluated patients’ perceptions and preferences of the Benepali autoinjector versus the Enbrel MYCLIC autoinjector in the same five European countries.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe

et al. 2016

Self Cite

View full text Add to dashboard Cite

IntroductionBenepali® was the first etanercept (Enbrel®) biosimilar to be approved in the European Union. Both Benepali and Enbrel are available as autoinjector devices. In a recent survey, nurses from France, Germany, Italy, Spain, and the United Kingdom (UK) reported that their patients with rheumatoid arthritis (RA) would prefer the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. To determine whether patients’ perceptions were similar to those of the nurses, this survey evaluated patients’ perceptions and preferences of the Benepali autoinjector versus the Enbrel MYCLIC autoinjector in the same five European countries.MethodsPatients with RA using the Enbrel MYCLIC autoinjector participated in a 25-min, face-to-face questionnaire-interview. Patients were also shown an instructional video and device-handling leaflet, received a live demonstration on the Benepali autoinjector, and had access to both Benepali and Enbrel MYCLIC training autoinjectors. Patients rated the importance of ten autoinjector attributes on a seven-point scale (1 = not important at all; 7 = extremely important) and provided their autoinjector preferences based on specific attributes. Patients also gave their opinion on which autoinjector they would prefer to use for self-injection.ResultsOverall, 220 patients participated in the survey (France, n = 30; Germany, n = 65; Italy, n = 67; Spain, n = 12; UK, n = 46). ‘Easy to operate the self-injection’ was ranked as the most important attribute (mean score of 6.8), followed by ‘easy to grip’ (6.5), and ‘intuitive/self-explaining usage’ (6.3). Patients preferred the Benepali autoinjector, with the attribute of ‘easier to operate’ being a strong differentiator compared to the Enbrel MYCLIC autoinjector. Most patients (74%) reported that they would prefer to use the Benepali autoinjector over the Enbrel MYCLIC autoinjector. ‘Easy to operate the self-injection’ and ‘button-free autoinjector’ were key drivers when selecting an autoinjector.ConclusionsPatients in Europe reported a preference for the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. This finding is consistent with results from a recently reported nurse survey. Funding: Biogen.Electronic supplementary materialThe online version of this article (doi:10.1007/s40744-016-0048-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionsupporting

confidence: 84%

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis

Chadwick

Zhao

Mysler³

et al. 2018

Curr Rheumatol Rep

View full text Add to dashboard Cite

Purpose of ReviewEtanercept was the first tumour necrosis factor inhibitor approved to treat rheumatoid arthritis (RA) in the United States (US) and Europe. The recent patent expiration of the etanercept originator ENBREL in Europe has facilitated the development of biosimilar products, creating the prospect of reduced treatment costs. In this article, we review the original trials for etanercept in RA to facilitate critical appraisal of biosimilar trial data.Recent FindingsTwo etanercept biosimilars are currently approved in Europe and/or the US, SB4 (Benepali) and GP2015 (Erelzi), having met the pre-specified equivalence criteria for biosimilarity. Trial data demonstrates subtle differences in clinical outcomes and adverse events between the biosimilars and the reference product (RP).SummaryThe development of etanercept biosimilars may reduce the financial burden of treating RA, but real-world data regarding efficacy and safety in comparison to the RP will be vital to assess for meaningful differences.

show abstract

Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study

et al. 2017

View full text Add to dashboard Cite

IntroductionBrenzys was developed as an etanercept biosimilar of Enbrel. The aim of this study was to assess preference and perceived ease of use for the new Brenzys autoinjector compared to the currently available marketed Enbrel MYCLIC autoinjector (Australia) and Enbrel SureClick autoinjector (Canada) for the treatment of rheumatoid arthritis (RA). Because RA affects manual dexterity, ease of use of an autoinjector is a particularly important consideration in developing effective self-delivery of long-term courses of therapy.MethodsPatients (N = 191) reporting a diagnosis of RA and nurses and rheumatologists (N = 90) with experience managing RA were shown how to use Brenzys and Enbrel autoinjectors (in counterbalanced order between participants), then they used each autoinjector by injecting into a pad simulating skin, and completed a questionnaire. Study sessions took place in Australia and Canada.ResultsA binomial test showed that significantly more patients indicated that the Brenzys autoinjector was easier to use than the Enbrel autoinjector (79% reporting Brenzys easier to use; p < 0.001, two-sided, 95% CI [73%, 85%]). In addition, significantly more nurses and rheumatologists with experience managing RA also indicated that the Brenzys autoinjector was easier to use (86%; p < 0.001, two-sided, 95% CI [77%, 92%) and that they would recommend the buttonless Brenzys autoinjector over the Enbrel autoinjector to patients (83%; p < 0.001, two-sided, 95% CI [74%, 90%]). Almost all patients who reported past experience using an Enbrel autoinjector (N = 17) reported on the basis of using the two devices in the study that they would prefer to switch their device to the Brenzys autoinjector rather than continue their course of therapy using the Enbrel autoinjector (16/17, 94%, 95% CI [71%, 100%]).ConclusionOn the basis of the study results, the Brenzys autoinjector was rated statistically significantly easier to use, and was overall preferred by patients and healthcare professionals with experience managing RA patients.FundingMerck & Co., Inc.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-017-0523-x) contains supplementary material, which is available to authorized users.

show abstract

Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe

Abstract: Biogen International GmBH.

Cited by 20 publications

References 23 publications

Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe

Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis

Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study

Contact Info

Product

Resources

About